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adherent patients were younger (20.9 vs. 25.8 years old, p= 0.011). The adjusted rate 
of thalassemia-related outpatient visits PPPM was higher in adherent patients (aIRR: 
1.11, p= 0.004). However, adherent patients incurred fewer thalassemia-related hos-
pitalizations (0.80, p= 0.002) and ER visits (0.64, p< 0.001). PPPM thalassemia-related 
medical costs followed a similar trend with slightly higher outpatient costs (aCD: 
$113, p= 0.504) and lower total costs (aCD: -$1,922, p= 0.056), mainly driven by lower 
inpatient costs (aCD: -$2,504, p= 0.052). Similar results were observed for all-cause 
RU and medical costs. While all-cause pharmacy costs were higher in adherent 
patients (aCD: $1,506, p< 0.001), non-ICT pharmacy costs was slightly lower (-$234, 
p= 0.200). CONCLUSIONS: This study shows that thalassemia patients adherent to 
ICT incurred more outpatient visits, which may be related to better disease moni-
toring and management, potentially resulting in the lower rates of acute care visits 
and related costs observed in this cohort. Enhanced adherence to ICT may reduce 
downstream costs associated with acute care, thereby reducing the financial burden 
of thalassemia from a payer’s perspective.
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OBJECTIVES: CDC has classified prescription drug abuse an epidemic with sig-
nificant societal economic burden. A 2009 systematic review on economic burden 
of prescription opioid misuse and abuse (POMA) found total cost (US, 2001) was 
~$8.6 billion and abusers’ annual medical costs were ~$14,000 higher than nona-
busers. The objective of this research was to update and synthesize all evidence 
around prevalence and costs of opioid abuse. METHODS: A systematic review was 
conducted to update the 2009 results by reviewing worldwide literature involving 
humans published in English from 2009-2014. The primary focus was prevalence 
and cost of POMA. Sources included PubMed, Embase, OpenSIGLE (for gray literature) 
and others. RESULTS: 5,281 citations were identified and 505 selected for inclusion; 
297 prevalence, 38 cost, 17 cost+prevalence, 124 consequences/sequelae, and 29 
other. CASP checklists were completed for 21 papers prioritized for further review; 
cost alone and cost+prevalence were included for final review. POMA prevalence 
ranged from 1.6 – 2.66/1000 in US privately insured and 5.0 – 8.7/1000 in Medicaid. 
5 year VA prevalence was 11.1/1000. Prevalence in the US increased from 1.8/1,000 
to 5.0/1,000 in Florida Medicaid and 0.5/1,000 to 1.6/1,000 in commercially insured 
from 1999-2006. Global illicit opioid dependence rate was 2.2/1000. Total US societal 
costs of POMA were $53.4 -$57.7 billion. Prescription opioid poisoning accounted for 
$15.9 billion. Excess annual medical costs in commercial claims data for patients 
with diagnosed opioid abuse and dependence was $9,456-$20,546. Similar results 
were seen in Medicaid and the VA which were ~$15,000. The per event cost for opioid 
abuse related ED/inpatient care was $18,891. CONCLUSIONS: Although comparison 
of societal costs is difficult given differences in methodology and years studied, 
societal costs increased from $8.6 billion in 2001 to over $55.7 billion in 2007. POMA 
is a societal problem and requires action by government, opioid manufacturers, 
practitioners and payers.
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OBJECTIVES: To investigate the demographic distribution and health care burden 
of patients diagnosed with ankylosing spondylitis (AS) using Medicare fee-for-
service (FFS) data. METHODS: A retrospective analysis was performed using the 
100% Medicare FFS Datasets from October 1, 2008 through December 31, 2012. 
Patients diagnosed with AS were identified using International Classification of 
Diseases, 9th Revision, Clinical Modification diagnosis code 720.0, and the first 
diagnosis date was designated as the index date. All patients were required to 
have continuous medical and pharmacy benefits 1-year pre- (baseline period) 
and post-index date (follow-up period). Health care resource utilization and costs 
during the baseline and follow-up periods were calculated. RESULTS: A total of 
8,990 AS patients were included in the study. The average age at diagnosis was 75 
years. Nearly 88.7% of patients were white, 62.97% were women and many resided 
in the South U.S. region (40.33%). The most common baseline comorbidities were 
chronic obstructive pulmonary disease (33.20%), diabetes (30.50%), cerebrovascular 
disease (22.65%) and congestive heart failure (18.85%). During the follow-up period, 
73.04% of patients had inpatient admissions, 52.31% had emergency room visits, 
91.43% had outpatient office visits, 91.43% had outpatient visits and 57.67% had 
pharmacy visits, resulting in average costs of, $37,077, $298, $5,397, $5,695 and 
$6,668, respectively. The average total costs were $49,440 during the follow-up 
period. The four most frequently prescribed medications for AS were prednisone 
hydrocodone (3.59%), bit/acetaminophen (3.17%), methotrexate sodium (2.79%) 
and levothyroxine sodium (2.42%). CONCLUSIONS: AS patient demographic and 
clinical characteristics in the Medicare population were assessed. Study patients 
were often diagnosed with comorbid conditions, and had high health care utili-
zation and costs.
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OBJECTIVES: Assess the timing of biologic initiation and associated healthcare uti-
lization and costs among psoriasis (PsO) patients. METHODS: Adults (18-64 years) 
with ≥ 2 PsO diagnoses (ICD-9-CM= 696.1) after 4/30/2004, ≥ 1 non-biologic pharma-
cologic systemic treatment (“non-biologic”) after the first observed diagnosis, and 
≥ 1 biologic treatment after the first non-biologic were selected from a de-identified 
US-based claims database. The index date was the date of the first biologic after 
the first non-biologic prescription fill. Patients had continuous eligibility during the 
12-months before (baseline) and 24-months following (study period) the index date. 
Patients were categorized into two cohorts based on days from the first non-biologic 
to index date: “> 180-days” and “≤ 180-days”. Study period utilization and costs were 
compared between cohorts using unadjusted and multivariable adjusted analy-
ses. RESULTS: There were 759 “> 180-days” and 881 “≤ 180-days” patients identified. 
During baseline, more patients in the“≤ 180-days” cohort had psoriatic arthritis 
compared to the “> 180-days” cohort (38.3% vs. 31.1%). “≤ 180-days” patients incurred 
more inpatients visits; higher medical, inpatient, and outpatient costs; and lower 
pharmacy costs compared to “> 180-days” patients during baseline. During the study 
period, the “≤ 180-days” cohort had higher unadjusted number of emergency room 
(0.52 vs 0.45) and outpatient visits (36.03 vs 31.89) as well as higher total ($20,971 vs 
$17,922, excluding PsO biologic costs), medical ($15,577 vs $12,749), and outpatient 
costs ($11,466 vs $9,527) (all p-values< 0.05). Multivariable regressions adjusting for 
baseline characteristics confirmed the unadjusted results. The numeric difference 
in adjusted costs between cohorts was small (adjusted 24-month difference in total, 
medical, and pharmacy costs= $3,123, $1,851 and $2,464, p-value= 0.0609, 0.0016, and 
0.2202, respectively). CONCLUSIONS: PsO patients initiating biologics ≤ 180-days 
from the first non-biologic had more severe disease and higher costs at baseline. 
Over the 24-month study period, differences in healthcare utilization and costs 
between patients with different timing of biologic initiation were small and not 
clinically meaningful.
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OBJECTIVES: Chron’s disease and ulcerative colitis are clinically similar diseases, 
classified as serious inflammatory diseases mainly in the intestinal region. A cost 
minimization analysis was conducted in order to compare the costs of treatment 
of infliximab versus adalimumab in the treatment of ulcerative colitis and Chron´s 
disease. METHODS: Considering published data on network meta-analysis provid-
ing similar results on the efficacy of both treatments, a cost-minimization analy-
sis was developed under the public and private healthcare system perspective . 
Comparator prices were obtained from public available sources (government cen-
tralized purchased contracts in the Public Perspective and factory prices including 
taxes (PF18%) in the Private Perspective). Annual costs were calculated according to 
the dose described on drugs’ respective labels. The average weight per patient was 
64 kg, based on the only local clinical study in Chron´s Disease patients reporting 
weight found in a literature review. RESULTS: Annual costs were divided between 
induction (1st year) and maintenance (2ndyear and so forth) regimens. Annual 
cumulative costs for induction regimen were R$ 24,041.98 and R$ 22,874.32 on 
the public perspective and R$ 80,527.36 and R$ 88,007.36 on private perspective 
for infliximab and adalimumab, respectively. Maintenance regimen costs were 
R$ 18,031.49 and R$ 19,606.56 on the public perspective and R$ 60,395.52 and R$ 
75,434.88 on the private perpective for infliximab and adalimumab, respectively. 
Incremental costs on a 2-year time horizon was -R$ 407.41, in the public perspec-
tive, and -R$ 22,519.36, in the private perspective (infliximab is less costly than 
adalimumab). CONCLUSIONS: In the public perspective, although showing higher 
costs on the first year of treatment, infliximab is less costly on longer treatment 
duration. On the private perspective, infliximab is less costly regardless of time 
horizon or treatment regimen.
PSY27
adherence to iron chelation theraPY and aSSociated healthcare 
reSource utilization and coStS in medicaid PatientS with 
thalaSSemia
Vekeman F.1, Sasane M.2, Cheng W.Y.3, Agnihotram R.V.1, Fortier J.4, Duh M.S.5, Paley C.2, 
Adams-Graves P.6
1Groupe d’analyse, Montreal, QC, Canada, 2Novartis Pharmaceuticals Corporation, East Hanover, 
NJ, USA, 3Analysis Group, Boston, MA, USA, 4Groupe d’analyse, LtÃ©e, Montreal, QC, Canada, 
5Analysis Group, Inc., Boston, MA, USA, 6University of Tennessee, Memphis, TN, USA
OBJECTIVES: To compare all-cause and thalassemia-related healthcare resource uti-
lization (RU) and costs in thalassemia patients who are adherent vs. non-adherent 
to iron chelation therapy (ICT). METHODS: Healthcare claims databases from six 
state Medicaid programs (Florida, Iowa, Kansas, Mississippi, Missouri, and New 
Jersey) (1997-2013) were analyzed. Patients with ≥ 1thalassemia ICD-9 diagnosis 
code, ≥ 2 dispensings for deferoxamine or deferasirox, and ≥ 6 months of continu-
ous enrollment before first ICT dispensing were included. Adherence was defined 
as a medication possession ratio ≥ 0.80. All-cause and thalassemia-related RU and 
costs were evaluated per-patient-per-month (PPPM) during the treatment period. 
Adherent and non-adherent patients were compared using adjusted incidence rate 
ratios (aIRR) for RU, and adjusted cost differences (aCD). RESULTS: Of the 218 eligible 
thalassemia patients, 137(62.8%) were adherent. Baseline demographic and clinical 
characteristics were similar between adherent and non-adherent patients, although 
